In clinical studies of SLE patients, IFN-γ produced by CD8+ T cells is a key factor in enhancing indoleamine 2,3-dioxygenase (IDO) activity, which promotes the therapeutic effect of allogeneic MSCs in lupus (215). The gene discussed is IDO1; the disease is systemic lupus erythematosus.